Home » Stocks » BIIB

Biogen Inc. (BIIB)

Stock Price: $331.93 USD 6.53 (2.01%)
Updated Jul 26, 2021 4:00 PM EDT - Market closed
After-hours: $334.98 +3.05 (0.92%) Jul 26, 5:40 PM
Market Cap 49.62B
Revenue (ttm) 11.70B
Net Income (ttm) 1.92B
Shares Out 149.70M
EPS (ttm) 12.50
PE Ratio 26.55
Forward PE 18.12
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $331.93
Previous Close $325.40
Change ($) 6.53
Change (%) 2.01%
Day's Open 325.09
Day's Range 322.51 - 335.00
Day's Volume 1,269,250
52-Week Range 223.25 - 468.55

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

The company is moving into three billion-dollar areas.

1 day ago - The Motley Fool

CAMBRIDGE, Mass., July 23, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced it will share multiple oral and poster presentations from its Alzheimer's disease clinical development port...

3 days ago - GlobeNewsWire

Biogen's new — and controversial — Alzheimer's drug, Adhulem, made a modest $2 million in revenue in the first several weeks after its.

3 days ago - The Motley Fool

Biogen (NASDAQ: BIIB) launched in June a new Alzheimer's disease drug but its uptake so far has been slow, leading one notable Wall Street analyst to recommend a cautious approach towards the stock. Cos...

4 days ago - Invezz

AT&T, Crocs, Biogen top Q2 estimates, Didi shares dip as China regulatory woes persist

YouTube video

#AT&T Myles Udland, Brian Sozzi, and Julie Hyman breakdown more Q2 earnings, which include: AT&T stock rising as the company topped estimates due to a push from wireless subscriber additions, Crocs beat...

Other stocks mentioned: CROX, DIDI, T
4 days ago - Yahoo Finance

Biogen (BIIB) beats second-quarter estimates for both earnings and sales and ups sales guidance for 2021.

4 days ago - Zacks Investment Research

Biogen Inc. (BIIB) delivered earnings and revenue surprises of 24.29% and 6.41%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

4 days ago - Zacks Investment Research

Biotech giant Biogen said that it brought in about $1.6 million in sales from its controversial Alzheimer's drug last month after it was approved by the Food and Drug Administration earlier in June.

4 days ago - New York Post

Shares of Biogen (NASDAQ:BIIB) fell 0.3% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 44.64% over the past year to $5.68, which beat the estimat...

4 days ago - Benzinga

Biogen's Alzheimer's drug, Adhulem, generated $2 million in revenue in the first few weeks of its approval, the company said in its second-quarter earnings.

4 days ago - CNBC

Biogen Inc (NASDAQ: BIIB) posted Q2 adjusted EPS of $5.68 ahead of the consensus estimate of $4.55, but quarterly profit fell around 71% Y/Y to $448.5 million as competition intensified for the Company'...

4 days ago - Benzinga

Biogen Inc on Thursday reported a 70.9% fall in quarterly profit as competition intensifies for multiple sclerosis drug Tecfidera, once the company's flagship treatment.

4 days ago - Reuters

NOTE: ADUHELM TM (aducanumab-avwa) injection 100 mg/mL solution is indicated for the treatment of Alzheimer's disease. Treatment with ADUHELM should be initiated in patients with mild cognitive impairme...

4 days ago - GlobeNewsWire

Aduhelm is expected to be a bestseller for Biogen and was the first Alzheimer's drug to be granted “accelerated approval,” a decision the regulator's experts criticized and said there was not enough evi...

Other stocks mentioned: RHHBY
4 days ago - Forbes

Mirimus Inc has collaborated with Biogen Inc (NASDAQ: BIIB) to develop RNAi-based therapeutics targeting multiple, undisclosed neurological disease indications.  Terms of the collaboration are not discl...

5 days ago - Benzinga

NEW YORK, July 21, 2021 /PRNewswire/ -- Mirimus, Inc., a pioneer in RNAi therapeutic design and CRISPR/Cas9 gene editing technology implementation, today announced a strategic collaboration with Biogen ...

5 days ago - PRNewsWire

Both of these companies have successfully developed breakthrough medicines.

Other stocks mentioned: VRTX
5 days ago - The Motley Fool

Investor focus is likely to be on commercialization plans for new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports second-quarter earnings.

6 days ago - Zacks Investment Research

This biotech company could be a diamond in the rough -- for investors who can tolerate its share price volatility.

1 week ago - The Motley Fool

There are important things to watch with each of these stocks.

Other stocks mentioned: ABBV, MRNA, PFE
1 week ago - The Motley Fool

Biogen Inc. (BIIB) closed at $324.62 in the latest trading session, marking a -1.08% move from the prior day.

1 week ago - Zacks Investment Research

Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 0 4 0 Somewhat Bullish 1 1 4 1 Indifferent 0 1 5 0 ...

1 week ago - Benzinga

The medical community has not been entirely convinced of the U.S. FDA's decision to approve Biogen Inc's (NASDAQ: BIIB) Aduhelm drug to treat Alzheimer's last month. Some health insurers also declined c...

1 week ago - Invezz

Three hospitals won't administer new Alzheimer's drug

YouTube video

CNBC's "Squawk Box" team discusses a new setback for Alzheimer's drug as three hospitals won't administer it.

1 week ago - CNBC Television

Biogen shares drop as big clinics say they won't administer controversial Alzheimer's drug

YouTube video

Cleveland Clinic and Mt. Sinai won't administer Aduhelm, a controversial but recently FDA-approved Alzheimer's drug.

1 week ago - CNBC Television

U.S. indices were trading lower Thursday as investors weigh Fed Chair Powell's comments on inflation to the Senate banking panel.  The Invesco QQQ Trust Series 1 (NASDAQ:QQQ) fell by 0.7% to $360.52

Other stocks mentioned: AMD, QQQ
1 week ago - Benzinga

Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

FDA ‘abandoned its responsibility' in approving Biogen Alzheimer's drug: Doctor

YouTube video

Dr. Reshma Ramachandran, Physician-Fellow at the Yale National Clinician Scholars Program, joins Yahoo Finance to breakdown the concerns over the FDA approval of Biogen Alzheimer's drug. Watch the 2021 ...

1 week ago - Yahoo Finance

BIIB stock is losing out today, as two major hospitals have declined to use Biogen's controversial new Alzheimer's drug on their campuses. The post BIIB Stock: The Drug Ban News That Has Biogen Stumblin...

1 week ago - InvestorPlace

A pair of large hospitals have declined to administer Biogen Inc's (NASDAQ: BIIB) Alzheimer's treatment Aduhelm, Wall Street Journal reported. The Cleveland Clinic and Mount Sinai Health System in New Y...

1 week ago - Benzinga

Acting FDA Commissioner Janet Woodcock pushed back against media questions about the agency's controversial approval of Alzheimer's treatment, Aduhelm developed by Biogen Inc (NASDAQ: BIIB) and Eisai Co...

1 week ago - Benzinga

Acting FDA Commissioner Dr. Janet Woodcock pushed back against questions from a journalist about the approval of Biogen's Alzheimer's medication, Aduhelm.

1 week ago - CNBC

Biogen partners with InnoCare Pharma for orelabrutinib, a BTK inhibitor with the potential of treating multiple sclerosis. The drug is currently undergoing phase II study.

1 week ago - Zacks Investment Research

Biogen Inc (NASDAQ: BIIB) is paying $125 million upfront to work on InnoCare Pharma Limited's orelabrutinib, a small oral molecule Bruton's tyrosine kinase inhibitor (BTKi) for multiple sclerosis. InnoC...

1 week ago - Benzinga

CAMBRIDGE, Mass. and BEIJING, July 12, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and InnoCare Pharma Limited (HKEX: 09969) today announced that they have entered into a license and collaborati...

1 week ago - GlobeNewsWire

Several drugmakers have important clinical trial updates on the way.

Other stocks mentioned: NVS, PFE, QURE, RHHBY, SAGE
2 weeks ago - The Motley Fool

By Brandon Rakszawski, Senior ETF Product Manager The Morningstar Wide Moat Focus Index (the “Moat Index” or “Index”) underperformed the S&P 500® Index in June (1.15% vs. 2.33%, respectively).

2 weeks ago - ETF Trends

• Acting commissioner refers agency to inspector general

2 weeks ago - The Guardian

Biogen Inc. (NASDAQ:BIIB) shares came under pressure Friday after the Food and Drug Administration called for an investigation into the approval of the company's Alzheimer's treatment Aduhelm. What Happ...

2 weeks ago - Benzinga

“There continue to be concerns raised … regarding contacts between representatives from Biogen and FDA during the review process,” the acting commissioner wrote to acting Inspector General Christi Grimm.

2 weeks ago - New York Post

Acting FDA Commissioner Woodcock asked the independent Office of the Inspector General to investigate interactions between the agency and Biogen prior to the drug's approval.

2 weeks ago - CNBC

The FDA approves label update for Biogen's (BIIB) new Alzheimer's drug, Aduhelm. The updated label narrows the patient population, which is eligible for the drug.

2 weeks ago - Zacks Investment Research

The company faces hard questions from a House committee about the pricing of Alzheimer's disease drug Aduhelm.

2 weeks ago - The Motley Fool

CAMBRIDGE, Mass. and NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- Today, access to the world's largest browsable resource linking rare protein-coding genetic variants to human health and disease was laun...

2 weeks ago - GlobeNewsWire

The broader averages are doing great, but buying and shorting these 3 blue-chip stocks is a calculated way to beat the market. The post 3 Blue-Chip Stocks to Trade Right Now appeared first on InvestorPl...

Other stocks mentioned: AMZN, INTC
2 weeks ago - InvestorPlace

Even with markets suffering, there were still some positives on Wall Street.

Other stocks mentioned: GNOG
2 weeks ago - The Motley Fool

Biogen Inc. (NASDAQ:BIIB) shares are lower after the company announced an updated label for its recently-approved Alzheimer's treatment Aduhelm. What Happened: Biogen, which is partnering with Japan's E...

2 weeks ago - Benzinga

ADUHELM should be initiated in patients with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's dementia ADUHELM should be initiated in patients with mild cognitive impairment due ...

2 weeks ago - GlobeNewsWire

Breaking down the costs of Biogen's billion-dollar Alzheimer's drug

YouTube video

CNBC's Meg Tirrell reports on the controversy over Biogen's Alzheimer's drug, which costs an average of $56,000 per year.

2 weeks ago - CNBC Television

An unusually lenient FDA is a knife that cuts both ways for Biogen.

Other stocks mentioned: LLY
2 weeks ago - The Motley Fool

About BIIB

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treati... [Read more...]

Industry
Drug Manufacturers-General
IPO Date
Sep 16, 1991
CEO
George Scangos
Employees
9,100
Stock Exchange
NASDAQ
Ticker Symbol
BIIB
Full Company Profile

Financial Performance

In 2020, Biogen's revenue was $13.44 billion, a decrease of -6.49% compared to the previous year's $14.38 billion. Earnings were $4.00 billion, a decrease of -32.06%.

Financial Statements

Analyst Forecasts

According to 33 analysts, the average rating for Biogen stock is "Hold." The 12-month stock price forecast is 404.41, which is an increase of 21.84% from the latest price.

Price Target
$404.41
(21.84% upside)
Analyst Consensus: Hold